Identification of Vitamin B1 metabolism as a tumor-specific radiosensitizing pathway using a high-throughput colony formation screen
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Supplementary Figures S1, S3 and Tables S1-S3 transporter where it is readily converted into its active form, thiamine pyrophosphate (TPP) by TPK1. TPP is a co-factor for transketolase (TKT), an enzyme in the non-oxidative pentose phosphate pathway (PPP), which catalyzes from glyceraldehyde 3-phosphate (G3P) and sedoheptulose 7-phosphate (S7P) the production of ribose-5 phosphate (R5-P), the sugar phosphate backbone of deoxynucleotide triphosphates (dNTPs). TPP can also be transported into the mitochondria by thiamine pyrophosphate carrier (TPC) and used as a prosthetic group for pyruvate dehydrogenase (PDH) and α-ketogluturate dehydrogenase (α-KGDH).
Thiamine metabolism can be perturbed by THTR1 and TPK1 knockdown, reducing thiamine uptake and production of TPP, respectively. In addition, disruption of thiamine metabolism can be achieved by the thiamine analogue pyrithiamine hydrobromide (PyrH), reducing TPP levels and possibly also thiamine uptake directly. As less TPP is available as a co-factor for TKT, the production of R5-P is decreased. This results in an inhibition of nucleotide production, reducing the cell's capability to repair DNA after irradiation and increasing cell death. The mitochondrial functions of TPP do not appear to be linked with radiosensitivity as knockdown of the mitochondrial transporter, TPC, did not affect radiosurvival. 
